CD20-positive T-cell Lymphoma with Indolent Clinical Behaviour

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.38, Iss.3, 2010-06, pp. : 1170-1174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma

By Foss Francine M

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 9, 2011-09 ,pp. : 1141-1152

Informa Healthcare

Access to resources Recommend Favorite

Pralatrexate: evaluation of clinical efficacy and toxicity in T-cell lymphoma

By Shimanovsky Alexei Dasanu Constantin A

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 4, 2013-03 ,pp. : 515-523

Informa Healthcare

Access to resources Recommend Favorite

Romidepsin: In the Treatment of T-Cell Lymphoma

By Yang Lily P.H.

Drugs, Vol. 71, Iss. 11, 2011-07 ,pp. : 1469-1480

Adis International

Access to resources Recommend Favorite

Management of cutaneous T-cell lymphoma

By Duhovic Chris Child Fiona Wain E Mary

Clinical Medicine, Vol. 12, Iss. 2, 2012-04 ,pp. : 160-164

Royal College Of Physicians

Access to resources Recommend Favorite

Emerging drugs for T-cell lymphoma

By Dickinson Michael Prince Henry Miles

Expert Opinion on Emerging Drugs, Vol. 19, Iss. 2, 2014-06 ,pp. : 201-213

Informa Healthcare

Access to resources Recommend Favorite